Record High Suicide Deaths Signal Urgent Need for Innovation
More than 49,000 Americans died by suicide in 2022, representing a 3% jump over the previous year and the highest number in U.S. history.
Read More
Johnson & Johnson’s Spravato Surges Toward Blockbuster Status
Johnson & Johnson's depression nasal spray Spravato continues its impressive growth trajectory, generating $414 million in Q2 2025 revenue.
Read More
Breakthrough Study: Ibogaine and Magnesium Dramatically Reduce PTSD Symptoms
Stanford Medicine researchers have unveiled results from a revolutionary treatment combining ibogaine with magnesium that reduces PTSD.
Read More
Trump’s VA Secretary Pushes for Psychedelic Therapy Despite Regulatory Hurdles
VA Secretary Doug Collins continues his passionate advocacy for psychedelic therapy access to achieve genuine healing for America's veterans.
Read More
Doctor Pleads Guilty in Matthew Perry Ketamine Case
Dr. Salvador Plasencia pleaded guilty to distributing ketamine to Matthew Perry in the weeks before the "Friends" star's fatal overdose.
Read More
Breakthrough Study Reveals Unexpected Allies in Eating Disorder Treatment
In a large study, cannabis and psychedelics emerged as the most highly rated treatments for treating eating disorders.
Read More
Psychedelics Show Promise for Smoking Cessation Research
Classic psychedelics like psilocybin and LSD may help people quit cigarettes, but researchers caution that evidence remains preliminary.
Read More
Colorado Considers Ibogaine as Next Regulated Psychedelic Medicine
Colorado is on the verge of becoming the first state to regulate ibogaine, a powerful plant derived psychedelic with promising applications.
Read More
Michigan Lawmaker Pushes to Decriminalize Psilocybin for PTSD Treatment
Michigan state Rep Mike McFall introduced legislation to decriminalize psilocybin possession for individuals diagnosed with PTSD.
Read More
California Governor Embraces Psychedelic Therapy While Fearing Corporate Takeover
California Governor Gavin Newsom has said that his state is "all in" on expanding psychedelic therapy access.
Read More